Company Analysis
Sign in

XORTX Therapeutics Inc. (XRTX)

Nasdaq: XRTX · Pharmaceutical Preparations · Vancouver, BC · filing with the SEC since 2018
Full chart Alerts Compare
Grade5.6
◀ Past 5.5● Present 5.1▶ Future 6.2
8 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2021, as filed
Revenuen/a
Net income-C$1.7M-28.6%
Earnings per sharen/a
Operating cash flow-C$6.1M-732.3%
CashC$18.9M+10906.7%
Debtn/a
Shareholders’ equityC$16.7M+1232.4%
Shares, dilutedn/a
Return on equity-9.9%
The recordfrom its filings
Filings in 202639
Newest filingOct 8 · 6-K
Annual reportMar 20, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted1
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
192021
As filed, in CAD. Nothing here is a forecast.

News

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton XRTX · research, not advice